Based on the positive results obtained from the ADAURA trial, the NEOADAURA trial is a phase III, randomized, controlled, three-arm, multi-center study evaluating the benefit and safety of neoadjuvant osimertinib alone or in combination with chemotherapy, versus standard-of-care chemotherapy alone, in patients with resectable EGFR mutant NSCLC (NCT04351555) (Table 6). This evidence concerns the gene EGFR and non-small cell lung carcinoma.